Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

OBJECTIVES: To perform a literature review and develop recommendations for the use of rituximab in ANCA-associated vasculitis. METHODS: A committee of experts (five rheumatologists, five nephrologists and one paediatrician) conducted a modified Delphi exercise to identify five topics for a systemat...

Полное описание

Библиографические подробности
Главные авторы:	Guerry, M, Brogan, P, Bruce, I, D'Cruz, D, Harper, L, Luqmani, R, Pusey, C, Salama, A, Scott, D, Savage, C, Watts, R, Jayne, DR
Формат:	Journal article
Язык:	English
Опубликовано:	2012

Схожие документы

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
по: Flossmann, O, и др.
Опубликовано: (2006)

Anti-neutrophil cytoplasmic antibody associated vasculitis following rituximab: Outcomes of 50 patients in a tertiary single centre
по: Fahidah Alenzi, и др.
Опубликовано: (2023-09-01)

Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.
по: Latimer, N, и др.
Опубликовано: (2014)

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
по: Latimer, N, и др.
Опубликовано: (2014)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
по: Hellmich, B, и др.
Опубликовано: (2007)

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.
по: Basu, N, и др.
Опубликовано: (2014)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
по: Alan D. Salama
Опубликовано: (2020-01-01)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
по: Mukhtyar, C, и др.
Опубликовано: (2006)

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
по: Luqmani, R, и др.
Опубликовано: (2017)

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis
по: Pearce, F, и др.
Опубликовано: (2017)

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)
по: Mukhtyar, C, и др.
Опубликовано: (2008)

Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis
по: Michael A Paley, и др.
Опубликовано: (2019-01-01)

The United Kingdom and Ireland Vasculitis Registry: Cross-sectional data on the first 3195 patients with a focus on anti-neutrophil cytoplasm – associated vasculitis and giant cell arteritis
по: Luqmani, R, и др.
Опубликовано: (2017)

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
по: Robson, J, и др.
Опубликовано: (2017)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
по: Merkel, P, и др.
Опубликовано: (2009)

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
по: de Groot, K, и др.
Опубликовано: (2009)

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
по: Robson, J, и др.
Опубликовано: (2014)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
по: Jones, R, и др.
Опубликовано: (2010)

Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases.
по: Feldmann, M, и др.
Опубликовано: (2006)

Is rituximab “The Wonder Drug” for antineutrophil cytoplasmic antibodies-associated vasculitis?
по: Saket Jha, и др.
Опубликовано: (2019-01-01)

Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis
по: Enrique Morales, и др.
Опубликовано: (2025-01-01)

Glucocorticoid Minimization in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An International Survey of Clinicians
по: David Massicotte-Azarniouch, и др.
Опубликовано: (2024-08-01)

Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis
по: Thomas Hellmark, и др.
Опубликовано: (2019-03-01)

Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
по: Jones, R, и др.
Опубликовано: (2009)

A disease-specific patient-reported outcome for anti-neutrophil cytoplasmic antibody–associated vasculitis: scale structure and measurement properties of the anti-neutrophil cytoplasmic antibody-associated vasculitis patient-reported outcome measure
по: Robson, J, и др.
Опубликовано: (2017)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
по: Luqmani, R, и др.
Опубликовано: (2017)

The role of neutrophils in vasculitis associated with antineutrophil cytoplasmic antibodies
по: E. N. Vorkel, и др.
Опубликовано: (2024-12-01)

Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
по: Zhi-Ying Li, и др.
Опубликовано: (2020-08-01)

Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives
по: Moog P, и др.
Опубликовано: (2015-11-01)

Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: A case report
по: Xinyu Weng, и др.
Опубликовано: (2022-03-01)

Eular recommendations for vasculitis
по: Luqmani, R, и др.
Опубликовано: (2007)

Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.
по: Walsh, M, и др.
Опубликовано: (2011)

Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis
по: Despina Michailidou, и др.
Опубликовано: (2022-06-01)

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
по: Lapraik, C, и др.
Опубликовано: (2007)

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
по: Ntatsaki, E, и др.
Опубликовано: (2014)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Kidney Transplantation
по: Valentina Binda, и др.
Опубликовано: (2021-12-01)

Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis
по: Cheng-Hua Weng, и др.
Опубликовано: (2019-12-01)

Clinical significance of HEp-2 cell cytoplasmic patterns in anti-neutrophil cytoplasmic antibody associated vasculitis
по: Naidan Zhang, MS, и др.
Опубликовано: (2022-06-01)

Long- term outcome of paediatric patients with ANCA vasculitis
по: Pusey Charles D, и др.
Опубликовано: (2011-06-01)

Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients
по: Laura S. van Dam, и др.
Опубликовано: (2020-12-01)